By Ian Walker


Deepverge PLC said Thursday that its enhanced monitoring equipment is to be installed as part of the U.K. Government's national Covid-19 infrastructure trial.

The environmental and life-sciences company said the equipment is worth 480,000 pounds ($659,520) and it expects to get revenue from installations next fiscal year, provided the trial is successful.

The trial is expected to last until the end of February 2022.

The multiple-unit installation consists of six upgraded Microtox toxicity monitoring and new models of the Microtox PD range for SARS-CoV-2 and other pathogen monitoring, Deepverge said.

"Deepverge is well-placed to capitalize on current and future opportunities to work with governments, industries bodies and private companies to create a co-ordinated solution, not only to the current global pandemic but also future health challenges," Chief Executive Gerry Brandon said.

Shares at 0952 GMT were up 2.25 pence, or 8.5%, at 28.75 pence.


Write to Ian Walker at


(END) Dow Jones Newswires

October 28, 2021 06:13 ET (10:13 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Integumen (LSE:SKIN)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Integumen Charts.
Integumen (LSE:SKIN)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Integumen Charts.